Login to Your Account


Attacking major depressive disorder

Allergan plc exercised its option to acquire AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator that was discovered by Aptinyx Inc. and advanced under an ongoing research collaboration between the companies. Allergan gained option rights to certain small molecules from the Aptinyx discovery platform under a research collaboration initiated in conjunction with its 2015 acquisition of Naurex Inc., which simultaneously spun out Aptinyx and its platform. 

more »


Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.

READ MORE »

Opinion


Partners in Focus